Viewing data from:

KAITLIB FE

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE | A203448 | LUPIN LTD

1 strength0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
WARNER CHILCOTT COMPANY, LLC v. LUPIN LTD. et al 3:2011cv07228 1 patentANDA 203448norethindrone and ethinyl estradiol	D.N.J.	2011-12-12	Terminated 2014-04-29	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Medicare Part D Spending

CMS annual spending data for Kaitlib Fe (2023)

Total Spending

$27K

Total Claims

228

Beneficiaries

Avg Cost/Unit

$1.90

Spending Trend

$28K(2019)→$31K(2020)→$30K(2021)→$32K(2022)→$27K(2023)

YoY Change:-23.3%

5yr CAGR:-5.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.025MG;0.8MG

0 patents0 exclusivities▴

TABLET, CHEWABLE;ORAL | Approved: Dec 17, 2015

No patent or exclusivity listings for this strength.